DUBLIN–(COMMERCIAL WIRE)–The “Global Celiac Disease Market Research and Forecast 2022-2028” Report has been added to ResearchAndMarkets.com offering.
The global celiac disease market is anticipated to grow significantly at a CAGR of 8.5% during the forecast period.
Celiac disease is a digestive disorder in which the body has trouble absorbing nutrients such as lipids, calcium, iron, and folic acid. It is an autoimmune disease induced by eating gluten, which damages the inner lining of the small intestine. Various diseases and conditions, including neurological abnormalities, infertility, reduced bone density, and some cancers, can be caused by the disease.
People with type 1 diabetes, Down syndrome, autoimmune thyroid disease, microscopic colitis, Addison’s disease, and rheumatoid arthritis are at risk for this inherited condition. Furthermore, the market for celiac disease therapy is anticipated to increase significantly in the forecast period, due to the development of several anti-inflammatory drugs and therapeutic vaccines that will replace or enhance a gluten-free diet.
The organization of various awareness programs and initiatives taken by the government in various nations for the treatment of celiac disease is an important factor that is driving the growth of the global celiac disease market. With such actions, the government can significantly stimulate the growth of the market.
In addition, there are numerous funds available for R&D operations, which is driving the expansion of the market. For example, in 2015 in Italy, children and adults with certain symptoms are tested for celiac disease. Diagnosed celiacs receive coupons worth up to $168 per month to spend on specially prepared gluten-free meals. Additionally, the Italian Celiac Association and the government educate restaurants on how to treat celiac disease. Gluten-free meals are even available in hospitals, schools, and other public canteens.
Impact of the COVID-19 pandemic on the global celiac disease market
The global celiac disease market is affected by the COVID-19 pandemic in December 2019. The excruciating need to screen and test large numbers of patients for possible SARS-Cov-2 infection is the most pressing problem. common for governments in all countries affected by COVID-19. countries. As the rapid spread of the new virus continues to impact communities around the world, celiac disease susceptibility and risk levels have become a source of concern for the celiac community.
The limits imposed to combat COVID-19 may have an impact on the treatment of celiac disease and eating gluten-free, which is now the only treatment option for celiac disease. Aside from that, major players were focusing on clinical trials for celiac disease therapies, due to pandemic trials being put on hold negatively impacting market growth. The market will witness a “V” shaped recovery in the near future due to the restart of activities in the major economies.
Market Player Perspectives
Key players in the global celiac disease market include Abbott Laboratories, Eli Lilly & Co, Novartis AG, Johnson & Johnson, BioLineRx Ltd., Amgen Inc., Siemens AG, and Bayer AG, among others.
Market players are considerably contributing to the growth of the market by adopting various strategies including mergers and acquisitions, collaborations, financing, and new product launches to stay competitive in the market.
The report covers
2020 Market Value Data Analysis and Forecast to 2027.
Annualized market revenue ($ million) for each market segment.
Analysis by country of the main geographic regions.
Key companies operating in the global celiac disease market. Subject to data availability, information related to new product launches and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and expansion strategies.
Competitive strategies identifying ‘who-is-where’ in the market.
Key Topics Covered:
1. Summary of the report
2. Market overview and information
2.1. Scope of the Report
2.2. Analyst insights and current market trends
2.2.1. Key results
3. Competitive landscape
3.1. Key Company Analysis
3.1.2. Financial analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players
4. Market determinants
5. Market segmentation
5.1. Global celiac disease market by type of treatment
5.2. Global Celiac Disease Market by Type of Diagnosis
5.3. Global celiac disease market by end user
6. Regional Analysis
7. Company profiles
7.1. Abbott Laboratories
7.2. AbbVie Inc.
7.3. ADMA Biologicals, Inc.
7.4. amgen inc.
7.5. Bayer AG
7.6. Bio Rad Laboratories, Inc.
7.7. BioLineRX Ltd.
7.8. Boston Scientific Corporation.
7.9. Bristol-Myers Squibb Co.
7.10. Calypso Biotech S.A.
7.11. ChemoCentryx, Inc.
7.12. Eli Lilly and company.
7.13. GlaxoSmithKline plc
7.14. ImmunogenX, Inc.
7.15. Janssen Pharmaceuticals, Inc.
7.16. Johnson & Johnson Services Inc.,
7.17. Merck & Co., Inc.,
7.18. Sanofi SA
7.19. ThermoFisher Scientific Inc.
7.20. ZEDIRA GmbH
For more information on this report, visit https://www.researchandmarkets.com/r/azvqcg